

EUnetHTA & Assessment of Value

European network for
Health Technology Assessment

Luciana Ballini - BSc- MSc
Chair of the EUnetHTA Plenary Assembly
Lead Researcher
Observatory for Health Innovations
Agenzia Sanitaria e Sociale Regionale - Italy


I declare I have no conflicts of interest

Participants in EUnetHTA JA2


EUnetHTA Partners and Associates

69 Partner organisations designated by Ministries of Health

Large number of regional agencies and non-for-profit organisations that produce or contribute to HTA




The timeline of reaching a sustainable and permanent HTA cooperation in Europe



Sustainable

EUnetHTA Collaboration Objectives

Project → JA1 → JA2 → JA3




Health Technology Assessment

- * Health technology assessment (HTA) is a multidisciplinary process that summarises information about the medical, social, economic and ethical issues related to the use of a health technology, in a systematic, transparent, unbiased, robust manner.
- * Its aim is to inform the formulation of safe, effective health policies that are patient focused and seek to achieve best value.
- * Despite its policy goals, HTA must always be firmly rooted in research and the scientific method.



EUnetHTA Activities and Tools



The HTA Core Model®

Description


The HTA Core Model® is a methodological **framework for shared production and sharing of HTA information**

Purpose


To enable **production** of high quality **HTA information in a structured format** to support the **production** of local (national or regional) HTAs and **reuse** of existing information

The Domains of the HTA Core Model[®]


- assessing **dimensions of value**



EUnetHTA WP5 REA Pharmaceuticals



Early Dialogues



December 2012




September 2015

16 Medicines + 5 Medical Devices



European Cooperation in HTA



Harmonised definition of ATV

What does EUnetHTA do for it?

- Transparent and shared assessment process
- Joint assessment of products
- Joint advice on products' development

What would it do for EUnetHTA ?

- Prioritise medicines for (JOINT) assessment
- Rational use of joint assessments
- Provide interpretations of difference in effect size
- Prioritise medicines for early dialogue

Thank you

This presentation arises from the EUnetHTA Joint Action 2 which has received funding from the European Union, in the framework of the Health Programme

